Our Commitment to Grantees
The Michelson Prize & Grants team is committed to the success of our grantees, and we provide the support, both financially and administratively, for their research to thrive. The following are a few of the key benefits of applying for our funding:
- Access to Program Staff - We are available throughout all stages of the application and grant funding processes to answer your questions.
- Exceptional Feedback - You can count on getting a thorough and well-considered review from members of our world-class Scientific Advisory Board, who were handpicked to provide a range of expertise on this topic.
- High Approval Rates - As a mission-driven and product-focused program, we fund research based on merit rather than a fixed approval rate. To date, more than 30% of proposals submitted have been approved by our Board.
- Solving a Global Challenge - We fund you to develop a product that will save the lives of millions of companion animals each year, and we will award you the $25 Million Michelson Prize if you succeed.
Here's what our grant recipients say about the Michelson Prize & Grants:
"The Michelson Grant gave us the opportunity to apply our expertise to a field that was completely unfamiliar to us. Instead of shunning our ideas, the Foundation encourages and challenges researchers from diverse fields to come up with out-of-the-box solutions for a nonsurgical sterilant... A goal that, when realized, will have huge worldwide impact."
-William Ja, PhD, Scripps Research Institute
"As a small business, it was such a pleasant surprise to discover how easy it was to work with the Found Animals Foundation. From the clear, helpful feedback on our original letter of intent, simple/fair negotiation of the contract language, streamlined reporting - everything about our interactions seemed well thought out to promote achieving a common research goal as a member of the Foundation team. What other funding agency makes you look forward to having them out for a site visit?"
-R. Scott Struthers, PhD, Crinetics Pharmaceuticals, Inc.